Breathe Well Live Well
|
Canada Approves Breo Ellipta for Adults With Asthma
Medscape Canadian regulators have approved the dry powder combination of fluticasone furoate and vilanterol (Breo Ellipta, GlaxoSmithKline/Theravance) for once-a-day treatment of asthma in adults with reversible obstructive airways disease, GlaxoSmithKline … |
View full post on asthma – Google News
Lung Disease News |
Breo Ellipta Now Approved as Asthma Treatment for Adult Patients in Canada
Lung Disease News GlaxoSmithKline (GSK) and VIBATIV® (telavancin) developer Theravance Biopharma, have just been granted Canadian approval for Breo Ellipta, a once-a-day maintenance treatment for asthma in patients who are at least 18 years old and have reversible … |
View full post on asthma – Google News
|
GSK Gets Canadian Approval For BREO ELLIPTA For Treatment Of Asthma In Adults
Nasdaq BREO® ELLIPTA is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25 mcg and 200/25 mcg, have been approved in Canada for use in asthma. BREO is administered … GSK-Theravance's Breo Ellipta gets Canadian approval to treat asthma in adults GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With … |
View full post on asthma – Google News
|
GSK Gets Canadian Approval for BREO ELLIPTA for Treatment of Asthma in Adults
RTT News GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) on Thursday announced the approval in Canada of BREO ELLIPTA for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease. GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With … |
View full post on asthma – Google News
Fox News |
FDA approves Glaxo, Theravance's Breo Ellipta asthma drug
Fox News The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger asthma … GlaxoSmithKline And Theravance: The Asthma Approval In Figures GlaxoSmithKline plc (ADR) Gets FDA Approval For Breo Ellipta To Treat Asthma … FDA Okays Breo Ellipta for Asthma in Adults |
View full post on asthma – Google News
Reuters |
US FDA approves Glaxo, Theravance's Breo Ellipta asthma drug
Reuters (Reuters) – The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger … GlaxoSmithKline plc (ADR) Gets FDA Approval For Breo Ellipta To Treat Asthma … FDA Okays Breo Ellipta for Asthma in Adults Glaxo Wins U.S. Approval to Sell Breo Only to Adults With Asthma |
View full post on asthma – Google News
Medscape |
FDA Okays Breo Ellipta for Asthma in Adults
Medscape The US Food and Drug Administration (FDA) has approved the combination of fluticasone furoate/vilanterol (Breo Ellipta, GlaxoSmithKline/Theravance) for the once-daily treatment of asthma in adults aged 18 years and older. Fluticasone furoate (FF) is an … FDA approves Glaxo, Theravance's Breo Ellipta asthma drug Glaxo Wins U.S. Approval to Sell Breo Only to Adults With Asthma FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US |
View full post on asthma – Google News
Reuters |
FDA approves Glaxo, Theravance's Breo Ellipta asthma drug
Reuters (Reuters) – The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger … Glaxo Wins U.S. Approval to Sell Breo Only to Adults With Asthma FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US FDA Okays Breo Ellipta for Asthma in Adults |
View full post on asthma – Google News
Lung Disease News |
FDA Rejects GSK's Breo Ellipta Asthma Therapy Use in Adolescents; Adult Use …
Lung Disease News GSK Incruse Ellipta COPD The U.S. Food and Drug Administration (FDA) ruled against the use of GlaxoSmithKline's new drug combination Breo Ellipta in asthma patients between the ages of 12 and 17. However, the Pulmonary-Allergy Drugs Advisory … |
View full post on asthma – Google News
|
GSK's Breo for asthma? FDA panel says yes–but only in adults
FiercePharma Good news for GlaxoSmithKline ($GSK): An FDA panel of experts says the efficacy and safety data for blockbuster wannabe Breo support the asthma indication it's gunning for in adults 18 and older. When it comes to children aged 12 to 17, though? UPDATE 2-FDA panel backs Glaxo asthma drug for adults, not adolescents U.S. Panel Backs Glaxo's Breo for Asthma in Adults, Not Kids FDA panel backs Glaxo asthma drug for adults, not adolescents |
View full post on asthma – Google News